New drug combo aims to protect cancer patients from transplant side effects
NCT ID NCT06008808
Summary
This early-stage study is testing whether adding one or two drugs to standard transplant care can better prevent two serious complications: graft-versus-host disease (where donor cells attack the patient's body) and cytokine release syndrome (a severe immune reaction). The trial involves 41 adults with blood cancers who are receiving a stem cell transplant from a half-matched family donor. Researchers want to see if these drugs can reduce complications while still allowing the transplant to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.